



UNITED STATES PATENT AND TRADEMARK OFFICE

12 JAN 2005

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

#3

James P. Demers
Brown Raysman Millstein Felder & Steiner, L.L.P.
900 Third Avenue
New York, NY 10022

In re Application of
AN, et al.
Application No.: 10/530,627
PCT No.: PCT/US02/34026
Int. Filing Date: 23 October 2002
Priority Date: 17 January 2002
Atty. Docket No.: 6319-4015
For: 2'-BETA-MODIFIED-6-SUBSTITUTED
ADENOSINE ANALOGS AND THEIR USE AS
ANTIVIRAL AGENTS

DECISION ON PETITION

UNDER 37 CFR 1.137(b)

The petition to revive under 37 CFR 1.137(b) filed 07 April 2005 in the above-captioned application is hereby **GRANTED** as follows:

Applicant's statement that "the entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional" and the prompt filing of the petition satisfies the requirement of 37 CFR 1.137(b)(3).

A review of the application file reveals that applicant has now provided payment of the full, U.S. Basic National Fee. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America.

This application is being returned to the United States Designated/Elected Office (DO/EO/US) for the preparation and mailing of a "Notification of Missing Requirements" (Form PCT/DO/EO/905) informing applicant that an executed oath or declaration of the inventors is required.

Derek A. Putonen
Attorney Advisor
Office of PCT Legal Administration
Tel: (571) 272-3294
Fax: (571) 273-0459